校正:戈特斯查克等人. 在制药热挤出中预测吞吐量和融温度. 制药2022 年,14 年,1757 年
Tobias Gottschalk1,2, Cihangir Özbay1, Tim Feuerbach2
1Laboratory of Solids Process Engineering, Department of Biochemical and Chemical Engineering, TU Dortmund University, Emil-Figge-Str. 68, 44227 Dortmund, Germany.
Pharmaceutics
|December 31, 2025
概括
本研究研究了[全期]对[具体结果]的影响. 我们的发现表明[关键结果的简要总结],强调了对[相关领域]的潜在影响.
科学领域:
- 生物医学研究生物医学研究
- 遗传学 遗传学 是一个
背景情况:
- [特定基因/蛋白质]在[疾病/过程]中的作用仍然不完全理解.
- 现有的治疗方法有局限性,需要新的方法.
研究的目的:
- 阐明[特定基因/蛋白质]在[生物途径/疾病]中的功能.
- 评估针对[疾病]的[特定基因/蛋白质]的治疗潜力.
主要方法:
- 在[细胞类型/模型生物体]中利用CRISPR-Cas9基因编辑.
- 进行定量实时PCR (qRT-PCR) 和西式涂抹,以评估基因和蛋白质的表达.
- 进行[特定测定]以测量[特定结果].
主要成果:
- 基因编辑导致[特定基因/蛋白质]表达减少[百分比]%.
- [具体结果] 在编辑的细胞/生物中显著改变 ([p值]).
- 在体内研究表明[动物模型的关键发现].
结论:
- 我们的发现确定[特定基因/蛋白质]作为[生物途径/疾病]的关键调节者.
- 向[特定基因/蛋白质]为[疾病]提供了一个有前途的治疗策略.
- 需要进一步的研究来将这些发现转化为临床应用.
相关概念视频
In Vitro Drug Dissolution: Compendial Testing Models I
584
Compendial dissolution methods are standardized procedures defined by pharmacopeias to evaluate the rate at which a drug dissolves in a specific medium. These methods ensure batch-to-batch consistency, enable quality control, and support the prediction of drug bioavailability. They are critical for both immediate and modified-release drug products.The apparatuses used for dissolution testing differ in their design and mechanical function, but all aim to simulate the physiological environment of...
584
In Vitro Drug Dissolution: Compendial Testing Models II
694
Various dissolution methods are utilized to assess a drug’s dissolution rate, including the flow-through cell, paddle-over-disk, cylinder, and reciprocating disk methods.The flow-through cell apparatus (USP (United States Pharmacopeia) method 4) comprises a reservoir for the dissolution medium and a pump that propels the medium through the cell containing the test sample. This method is crucial for assessing modified-release dosage forms with minimally soluble active ingredients,...
694
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
228
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
228
